Given that different ovarian cancer subtypes are associated with variable clinical manifestations and amounts of ascites production, the aim of the present study was to evaluate whether our previously observed mechanism of interaction between VEGF-A165 (hereafter named VEGF) - the most important angiogenic factor - and adhesion proteins in serous papillary cancer patients varies depending on histological type and tumor biology. This evidence concerns the gene VEGFA and ovarian cancer.